Watfa Al-Mamari is a developmental pediatrician who established the first developmental pediatric clinics in Oman in 2011. She has worked closely with academic institutions to ensure that developmental pediatrics is included in the curriculum for both undergraduate and postgraduate students. She has a special interest in autism and led the team to establish a national program in Oman to screen children for autism at 18 months of age.
Al-Mamari graduated from Sultan Qaboos University in Muscat, Oman, and later did her residency and fellowship at McGill University in Montreal, Canada.
Watfa Al-Mamari
Developmental pediatrician
Sultan Qaboos University
From this contributor
How one doctor made Oman a leader on autism in the Middle East
Developmental pediatrician Watfa Al-Mamari is building an autism program in Oman from the ground up.
How one doctor made Oman a leader on autism in the Middle East
By
Laura Dattaro
4 February 2020 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read